Ryan A. Crowley, BSJ; for the Health Public Policy Committee of the American College of Physicians *
Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations.
Acknowledgment: The authors thank Jorge Fuentes, MD, for his contributions to this article.
Financial Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-2481.
Requests for Single Reprints: Ryan A. Crowley, BSJ, American College of Physicians, 25 Massachusetts Avenue NW, Suite 700, Washington, DC 20001; e-mail, RCrowley@mail.acponline.org.
Author Contributions: Conception and design: R.A. Crowley.
Analysis and interpretation of the data: R.A. Crowley.
Drafting of the article: R.A. Crowley.
Critical revision of the article for important intellectual content: R.A. Crowley.
Final approval of the article: R.A. Crowley.
Administrative, technical, or logistic support: R.A. Crowley.
Collection and assembly of data: R.A. Crowley.
This article has been corrected. The original version (PDF) is appended to this article as a Supplement.
Electronic nicotine delivery systems (ENDS), which include electronic cigarettes, or e-cigarettes, are growing in popularity, but their safety and efficacy as a smoking cessation aid are not well understood. Some argue that they have the potential to reduce tobacco-related morbidity and mortality and could be a useful tool for reducing tobacco-related harm. Others express concern that the health effects of ENDS use are unknown, that they may appeal to young people, and that they may encourage dual use of ENDS and traditional tobacco products. Although ENDS are a new and unregulated product, the U.S. Food and Drug Administration has proposed regulations that would deem ENDS to be subject to the Family Smoking Prevention and Tobacco Control Act, which regulates cigarettes and other tobacco products. In this position paper, the American College of Physicians offers policy recommendations on ENDS regulation and oversight, taxation, flavorings, promotion and marketing, indoor and public use, and research. This paper is not intended to offer clinical guidance or serve as an exhaustive literature review of existing ENDS-related evidence but to help direct the College, policymakers, and regulators on how to address these products.
The most important roles that science can play in the current ECIG debate are to identify and then fill the substantial knowledge gaps that exist today. The review of the literature presented here highlights clearly that very little is known about the acute and longer-term effects of ECIG use for individuals and the public health, especially given the dramatic variability in ECIG devices, liquids, and user behavior.
Crowley RA, for the Health Public Policy Committee of the American College of Physicians. Electronic Nicotine Delivery Systems: Executive Summary of a Policy Position Paper From the American College of Physicians. Ann Intern Med. 2015;162:583–584. doi: https://doi.org/10.7326/M14-2481
Download citation file:
Published: Ann Intern Med. 2015;162(8):583-584.
Cardiology, Coronary Risk Factors, Smoking, Tobacco, Alcohol, and Other Substance Abuse.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use